An international phase III clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.
Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.
